Novartis AG Common Stock (NVS)

R&D Expenses

$2.76B

Quarterly · Period ending: · USD

NVS logo

NVS R&D Expenses

Latest reported$2.76B
NVS Quarterly R&D Expenses ($0.00 → $2.76B)
High-resolution chart · PNG

NVS r&d expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock R&D Expenses — Quarterly (USD)
Period endingR&D Expenses (USD)
2,758,890,000
2,740,000,000
2,836,784,000
2,944,000,000
2,727,000,000
2,366,000,000
2,842,000,000
2,392,000,000
2,367,000,000
2,421,000,000
2,567,000,000
3,925,000,000
2,304,000,000
2,575,000,000
2,442,000,000
2,542,000,000
2,498,000,000
2,320,000,000
2,409,000,000
2,380,000,000
2,400,000,000
2,351,000,000
2,333,000,000
2,146,000,000
2,441,000,000
2,060,000,000
2,853,000,000
2,199,000,000
2,051,000,000
2,299,000,000
2,399,000,000
2,147,000,000
2,126,000,000
1,982,000,000
2,502,000,000
2,239,000,000
2,062,000,000
2,169,000,000
2,584,000,000
2,224,000,000
2,190,000,000
2,041,000,000
2,472,000,000
2,190,000,000
2,206,000,000
2,067,000,000
2,537,000,000
2,161,000,000
2,178,000,000
2,210,000,000
2,697,000,000
2,216,000,000
2,247,000,000
2,297,000,000
2,621,000,000
2,191,000,000
2,285,000,000
2,235,000,000
2,523,000,000
2,475,000,000
2,397,000,000
2,188,000,000
2,592,000,000
2,548,000,000
1,893,000,000
2,037,000,000
2,148,000,000
1,825,000,000
1,802,000,000
1,694,000,000
1,834,000,000
1,942,000,000
1,767,000,000
1,674,000,000
1,847,000,000
1,552,000,000
1,529,000,000
1,502,000,000
1,538,000,000
1,404,000,000
1,253,000,000
1,131,000,000
1,472,000,000
1,191,000,000
1,096,000,000
1,087,000,000
1,234,000,000
1,062,000,000
964,000,000
947,000,000
1,092,000,000
878,000,000
943,000,000
843,000,000
1,094,000,000
676,000,000
715,000,000
0
0
0
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.